Indy Behavioral Health
- Ozone Therapy
- IV Therapy
- Transcranial Magnetic Stimulation (TMS)
- Hyperbaric Oxygen Therapy (HBOT)
- Ketamine Therapy
Indianapolis, IN
Indianapolis supports a regenerative medicine market shaped by both private clinics and regional academic medicine. Local referral networks run through Indiana University Health, Community Health Network, and Ascension St. Vincent, and stem cell practice in the area spans downtown, Carmel border, and the North Meridian corridor. Patient demand splits across three buckets: orthopedic injections for active adults and aging athletes, neurological and autoimmune protocols marketed to longevity-focused patients, and IV-based allogeneic products offered by private wellness clinics. The FDA classifies most stem cell injections for orthopedic, neurological, or longevity use as investigational biologics under 21 CFR Part 1271, meaning they require either a Biologics License or an active Investigational New Drug authorization. Autologous bone marrow and adipose products may qualify as Section 361 when minimally manipulated and used for homologous function. Indiana regulates physician practice through the Medical Licensing Board of Indiana. There is no state-specific stem cell statute, so federal 21 CFR Part 1271 rules apply. The 3 Indianapolis clinics listed below have been reviewed against our vetting criteria, including federal NPI lookup, OIG exclusion screening, and Indiana Medical Licensing Board licensure checks.
Regulatory context
Indiana cellular therapy is governed by 21 CFR Part 1271. Section 361 covers minimally manipulated HCT/Ps used for homologous use without premarket approval. Section 351 covers products that are more than minimally manipulated, used non-homologously, or combined with another article, and these require an IND for clinical use or a BLA for marketing. Most stem cell, stromal vascular fraction, and exosome therapies marketed in Indiana for orthopedic, neurologic, and longevity indications are Section 351 biologics that lack FDA approval. Indiana's market is concentrated around Indianapolis and includes both compliant academic IND research and direct-to-patient regenerative clinics.
The FDA has corresponded with Indiana providers offering cellular therapies, and warning letters have been issued to Midwest clinics with operations in or near Indiana. The Medical Licensing Board of Indiana can discipline physicians for unprofessional conduct including misleading regenerative medicine advertising. The Indiana Attorney General's Consumer Protection Division can pursue deceptive marketing under the Deceptive Consumer Sales Act. No high-profile federal injunction specific to Indiana stem cell clinics has been issued, but enforcement risk tracks federal action.
Explore related care